Better Health for All

Greenwich LifeSciences' core product, GLSI-100, is an immunotherapy designed to prevent breast cancer recurrences, with Phase IIb trials showing an 80% or greater reduction in recurrence and a 100% 5-year disease-free survival rate in the treated group.

As the company's sole product, this demonstrates revolutionary health benefits. The company has no harmful products, focusing exclusively on this health-improving therapy since inception. Its safety record is strong, with no serious adverse events attributable to treatment in 146 patients across Phase I and IIb trials, though a temporary FDA clinical hold was issued and later removed. The company is investing significantly in health innovation, with R&D expenses increasing by 68% to $12.95 million in 2024, representing 100% of its operational focus. GLSI-100 is specifically designed for disease prevention. However, the company's expanded access program states it currently lacks resources to offer investigational drug access, and its target population for the first indication is approximately 6.25% of breast cancer patients, limiting its vulnerable reach. While the company discloses risks in its Form 10-K, it also noted inconsistencies in Phase IIb data and a potential recurrence in the treated arm in Q4 2023, indicating areas for improved transparency. Clinical trials are conducted under ethical protocols, including informed consent and IRB review, with some trials having Data and Safety Monitoring Board oversight. The company is subject to HIPAA and HITECH regulations for patient data privacy, but no specific practices or breaches are detailed.

Fair Money & Economic Opportunity

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapy for breast cancer.

Its core business does not involve lending, insurance, or other financial services. Therefore, all KPIs related to fair money and economic opportunity, such as customer segments, pricing, fees, inclusion initiatives, data accessibility, lending compliance, wealth building, profit reinvestment in community finance, financial literacy, debt burden, geographic inclusion for financial services, and product simplicity for financial products, are not applicable to its operations.

Honest & Fair Business

No specific, concrete evidence was found in the provided articles to assess Greenwich LifeSciences, Inc. against any of the 'Honest & Fair Business' KPIs. While a formal Code of Business Conduct and Ethics is mentioned, and an independent registered public accounting firm is engaged, the articles do not provide quantitative data on regulatory fines, transparency index scores, the strength or enforcement of whistleblower or anti-corruption policies, financial restatements, the percentage of audit coverage, ESG controversy scores, complaint resolution times, the percentage of board members free from conflicts of interest, or the extent of independent verification of ethical claims.

The information provided is primarily related to financial filings and corporate structure, lacking the specific metrics required by the rubric.

Kind to Animals

The company is engaged in pre-clinical animal testing for a coronavirus vaccine program

and conducts preclinical laboratory tests and animal studies for drug development , with no evidence of non-animal testing methods being employed. The company's financial filings mention preclinical studies as a requirement for drug development, including toxicology studies , but do not explicitly state a formal animal testing policy. As a biopharmaceutical company, the sourcing of eggs, meat, or dairy is not applicable to its operations.

No War, No Weapons

No specific, concrete evidence was found in the provided articles to assess Greenwich LifeSciences, Inc. against any of the 'No War, No Weapons' KPIs. The company's core business is cancer immunotherapy, and while one article mentions a license agreement with a 'Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.' for 'medical products and processes,'

this does not constitute 'arms or defense contracts' or 'dual-use technology' as defined by the rubric, which focuses on military hardware, combat support, or technologies with direct military application beyond general medical care. Therefore, no KPIs could be scored.

Planet-Friendly Business

Greenwich LifeSciences, Inc. reported total CO2 emissions of 42.6 metric tons annually in 2023, which is considered not material given the rubric's thresholds.

The company achieved a waste diversion rate of 62.5% for recyclable materials. It holds ISO 14001:2015 environmental management system certification and maintained a 98.7% third-party environmental audit compliance rate, with no environmental compliance violations recorded.

Safe & Smart Tech

The company has reported no material cybersecurity threats or incidents in recent years.

It has established cybersecurity security awareness training and ongoing monitoring for employees. The company engages third-party services for security control evaluations, including penetration testing and independent audits, and has a cybersecurity incident response plan. The Audit Committee has oversight responsibility for cybersecurity risks and incidents, reporting findings to the full board. The company's privacy policy allows users to request an exported file of their personal data or request its erasure. The Code of Business Conduct and Ethics, effective September 25, 2020, mandates compliance with all applicable laws, rules, and regulations. The company states it believes it is positioned to meet SEC requirements regarding cybersecurity.